Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imre's Prosorba

This article was originally published in The Gray Sheet

Executive Summary

FDA is requiring data from a randomized clinical trial to be added to Imre's premarket approval application for its Prosorba immunoadsorption column for the treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS), the firm announced on March 22. Imre says it has had discussions with FDA regarding an investigational device exemption protocol, which will also include an evaluation of Prosorba as a treatment for Classic TTP/HUS. Imre is ready to begin the trials as soon as FDA issues an IDE.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel